Amneal Pharmaceuticals (AMRX) Total Debt (2017 - 2026)

Amneal Pharmaceuticals has reported Total Debt for 10 years, with the latest figure at $2.7 billion in Q2 2026.

• On a quarterly basis, Total Debt rose 8.22% year-over-year to $2.7 billion in Q2 2026; TTM through Jun 2026 was $2.7 billion, a 8.22% increase from a year earlier, with the FY2025 full-year figure at $2.6 billion, down 1.21% from the prior year.
• Total Debt was $2.7 billion for Q2 2026 at Amneal Pharmaceuticals, up from $2.6 billion in the prior quarter.
• The five-year high for Total Debt was $2.8 billion in Q2 2022, with the low at $2.5 billion in Q2 2025.
• Average Total Debt over 5 years is $2.6 billion, with a median of $2.6 billion recorded in 2023.
• The sharpest annual moves came in 2025 and 2026: Total Debt decreased 7.21% in 2025, then advanced 8.22% in 2026.
• Over 5 years, Total Debt stood at $2.7 billion in 2022, then dropped by 3.18% to $2.6 billion in 2023, then gained by 0.43% to $2.6 billion in 2024, then dropped by 1.21% to $2.6 billion in 2025, then grew by 3.55% to $2.7 billion in 2026.
• The last three Total Debt figures came in at $2.7 billion (Q2 2026), $2.6 billion (Q1 2026), and $2.6 billion (Q4 2025), per Business Quant data.